Why Denmark Ozempic Leverage in Greenland Talks Doesn’t Hold Up

The notion of Denmark’s Ozempic leverage in Greenland talks suggests that Copenhagen could use its control over the supply of semaglutide-based drugs like Ozempic to influence U.S. policy regarding Greenland. At first glance, the idea appears strategically clever: Denmark is home to Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy, which supply tens of millions of doses annually to the U.S. market.

However, this theory falters when placed under economic and logistical scrutiny.

The Reality Behind Denmark’s Pharmaceutical Power

Denmark manufactures the bulk of semaglutide’s active pharmaceutical ingredients, which are essential for treating diabetes and obesity. The drugs are in high demand across the U.S., and production has scaled aggressively. With Novo Nordisk’s market capitalization surpassing Denmark’s entire GDP, it’s clear the nation wields considerable influence in this sector.

That said, Denmark’s leverage on Ozempic in Greenland talks is limited by several structural barriers.

1. Supply Chain Interdependence

While Denmark produces the drug’s core compounds, final assembly and packaging occur in various global locations, including the United States. Any disruption from Denmark would not just hit the U.S.—it would ripple back to Danish workers, shareholders, and the broader European pharmaceutical ecosystem.

2. Trade Norms and Regulatory Barriers

Using a prescription drug as a geopolitical tool would violate trade agreements and pharmaceutical regulatory norms. Denmark’s credibility as a reliable trade partner would suffer, potentially opening the door to U.S. countermeasures. Regulatory retaliation—such as blocking or delaying FDA approvals for future Danish products—would be costly and difficult to contain.

3. Backlash Risk and Economic Fallout

Weaponizing drug exports would invite bipartisan condemnation in Washington. Denmark would also risk broader sanctions or retaliatory economic policies. Unlike fossil fuels or rare earth minerals, semaglutide is not irreplaceable. Over time, the U.S. could incentivize domestic alternatives, blunting Denmark’s edge permanently.

Greenland Strategy Needs a Broader Lens

The real challenge lies in securing Greenland’s strategic autonomy without provoking open confrontation. Instead of relying on Denmark’s leverage in Greenland talks, Copenhagen can strengthen its position through multilateral Arctic defense agreements, economic partnerships with Greenlandic institutions, and targeted investments in the island’s infrastructure and autonomy.

Strategic Alternatives

• Coordinate with NATO and the EU to establish Arctic governance frameworks
• Enhance logistics and defense cooperation tied to Greenland’s critical geography
• Elevate Danish scientific and military presence in the Arctic to deter encroachment
• Expand biotech and clean energy partnerships that bind the U.S. and Denmark through mutual innovation

Relying on semaglutide exports as leverage is neither sustainable nor credible. A robust Greenland strategy demands long-term structural moves—not pharmaceutical pressure tactics.